EFFECTS OF 6-MONTHS TREATMENT WITH DONEPEZIL AND RIVASTIGMIN ON RESULTS OF NEUROPSYCHOLOGICAL TESTS OF MMSE, NPI, CLOCK AND BENDER IN PATIENTS WITH ALZHEIMER'S DISEASE

EFFECTS OF 6-MONTHS TREATMENT WITH DONEPEZIL AND RIVASTIGMIN ON RESULTS OF NEUROPSYCHOLOGICAL TESTS OF MMSE, NPI, CLOCK AND BENDER IN PATIENTS WITH ALZHEIMER'S DISEASE

Alzheimer's disease is the most common degenerative disease of brain. Nowadays, the most common treatment being used to slow down disease progression, include Donepezil , Rivastigmine and Galantamine, which all of them act as inhibitors of acetyl cholinesterase. General purpose of our study was...

Full description

Bibliographic Details
Main Authors:	R. Abolfazli, S. Ghazanshahi M. Nazeman
Format:	Article
Language:	English
Published:	Tehran University of Medical Sciences 2008-04-01
Series:	Acta Medica Iranica
Subjects:	Alzheimer’s disease donepezil rivastigmine MMSE (mini mental state examination) NPI (neuro psychiatry inventory) clock drawing test
Online Access:	https://acta.tums.ac.ir/index.php/acta/article/view/3451

Similar Items

EFFECTS OF 6-MONTHS TREATMENT WITH DONEPEZIL AND RIVASTIGMIN ON RESULTS OF NEUROPSYCHOLOGICAL TESTS OF MMSE, NPI, CLOCK AND BENDER IN PATIENTS WITH ALZHEIMER'S DISEASE
by: R. Abolfazli, et al.
Published: (2008-05-01)

The Effects of Donepezil, Galantamine, Rivastigmine and Memantine on Mini-Mental State Examination and Mean Flow Velocity in Patients with Vascular Dementia: A Double-Blinded Randomized Clinical Trial
by: Farhad Iranmanesh, et al.
Published: (2020-03-01)

Development of novel salicylic acid–donepezil–rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer’s disease
by: Yi Zhou, et al.
Published: (2023-12-01)

Donepezil Regulates LPS and Aβ-Stimulated Neuroinflammation through MAPK/NLRP3 Inflammasome/STAT3 Signaling
by: Jieun Kim, et al.
Published: (2021-09-01)

Are there links between Alzheimer’s disease and ADHD? The efficacy of acetylcholinesterase inhibitors and NMDA receptor antagonists in controlling ADHD symptoms: a systematic review
by: Ramin Abdi Dezfouli, et al.
Published: (2024-02-01)

The effect of cholinesterase inhibitors on sleep in the patients with Alzheimer’s disease: an observational prospective study
by: Osman Korucu, et al.
Published: (2018-01-01)

Electrocardiographic Effects of Cholinesterase Inhibitors in Patients with Alzheimer’s Disease
by: Ayşe ÇOLAK, et al.
Published: (2022-12-01)

Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
by: Débora Nunes, et al.
Published: (2022-10-01)

Community Pharmacists’ Knowledge Regarding Donepezil Averse Effects and Self-Care Recommendations for Insomnia for Persons with AD
by: Marketa Marvanova, et al.
Published: (2017-07-01)

Rivastigmine–Bambuterol Hybrids as Selective Butyrylcholinesterase Inhibitors
by: Jie Wu, et al.
Published: (2023-12-01)

Rivastigmine als ondersteuning bij het dilemma van de behandeling van hallucinaties optredend bij ziekte van Parkinson
by: jmp Rovers, et al.
Published: (2024-02-01)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
by: Yasir Hasan Siddique, et al.
Published: (2022-01-01)

Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia
by: Yoon-Sang Oh, et al.
Published: (2015-05-01)

Validity and Reliability of the Clock Drawing Test in Older People
by: Massoumeh Sadeghipour Roodsari, et al.
Published: (2013-07-01)

Improvement in delirium and visuospatial function after rivastigmine in antimuscarinic toxicity: a case report
by: Matthew S. Correia, et al.
Published: (2023-12-01)

Predicting Scores on the Mini-Mental State Examination (MMSE) from Spontaneous Speech
by: Alma M. Bueno-Cayo, et al.
Published: (2022-09-01)

The specific features of using a rivastigmine transdermal formulation in Alzheimer’s disease
by: Elena Evgenyevna Vasenina, et al.
Published: (2012-09-01)

Detection of endogenous NPY release determined by novel GRAB sensor in cultured cortical neurons
by: Emma Kragelund Christensen, et al.
Published: (2023-07-01)

Alzheimer's disease - a review of medicinal substances and their derivatives
by: Marika Więcek, et al.
Published: (2024-02-01)

Safety of Cholinesterase Inhibitors and NMDA Receptors Antagonists for the Treatment of Patients with Dementia
by: A. P. Pereverzev, et al.
Published: (2019-12-01)

The Potential Effect of Insulin on AChE and Its Interactions with Rivastigmine In Vitro
by: Tahereh Jamshidnejad-Tosaramandani, et al.
Published: (2021-11-01)

Correlation of INECO Frontal Screening With Verbal Fluency Tasks and MMSE in Persian Healthy Population
by: Fatemeh Satarian, et al.
Published: (2018-02-01)

Mini-mental state examination (MMSE) scores in elderly Jordanian population
by: Said Dahbour, et al.
Published: (2021-01-01)

Comparison of Plasma NPY and Zinc Levels of Elite Weightlifters and Sedentaries
by: Abdulkerim Baltaci, et al.
Published: (2021-08-01)

Use of a rivastigmine transdermic patch in Alzheimer's disease and Parkinson's disease dementia
by: Lacramioara Perju Dumbrava, et al.
Published: (2009-03-01)

Optimized Rivastigmine Nanoparticles Coated with Eudragit for Intranasal Application to Brain Delivery: Evaluation and Nasal Ciliotoxicity Studies
by: Mansi Bhanderi, et al.
Published: (2021-10-01)

The Bidirectional Relationship of NPY and Mitochondria in Energy Balance Regulation
by: Diana Sousa, et al.
Published: (2023-02-01)

Mitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice
by: Constantin Kondak, et al.
Published: (2023-06-01)

The relevance of Mini Mental State Examination (MMSE) use on demential interdiction exams in judicial proceedings
by: Débora Mascella Krieger, et al.
Published: (2020-05-01)

RETRACTED: QbD-based rivastigmine tartrate-loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer's therapeutics
by: Deepshi Arora, et al.
Published: (2022-08-01)

Delirium Associated with Donepezil in a Patient with Alzheimer’s Disease: a Case Report
by: Kamyar Mollazadeh-Moghaddam, et al.
Published: (2013-03-01)

NPY derived from AGRP neurons controls feeding via Y1 and energy expenditure and food foraging behaviour via Y2 signalling
by: Yue Qi, et al.
Published: (2022-05-01)

Effects of Concentration, Temperature and Polymer Type on Drug Release from Montmorillonite-Donepezil Nanocomposites
by: Naser Tavakoli, et al.
Published: (2013-04-01)

Donepezil Treatment of Hypersomnia After COVID-19
by: Demet Aygün Üstel, et al.
Published: (2021-12-01)

Power-Delay-Profile-Based MMSE Channel Estimations for OFDM Systems
by: Sungmook Lim, et al.
Published: (2023-01-01)

Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer’s-like Tauopathy Mouse Model
by: Maciej Zadrozny, et al.
Published: (2024-04-01)

Novel Rivastigmine Derivatives as Promising Multi-Target Compounds for Potential Treatment of Alzheimer’s Disease
by: David Vicente-Zurdo, et al.
Published: (2022-06-01)

New Multitarget Rivastigmine–Indole Hybrids as Potential Drug Candidates for Alzheimer’s Disease
by: Leo Bon, et al.
Published: (2024-02-01)

Galantamine of rivastigmine pleister. Een beschrijvend onderzoek op een geheugenpolikliniek in Nederland
by: C.J. Wouters, et al.
Published: (2023-07-01)

In Situ<i>-</i>Forming Microparticles for Controlled Release of Rivastigmine: In Vitro Optimization and In Vivo Evaluation
by: Mohamed Haider, et al.
Published: (2021-01-01)